GE
Therapeutic Areas
Jazz Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Oncology Pipeline | Various Oncology Targets | Pre-Clinical to Clinical |
| Epidiolex/Epidyolex | Rare Epilepsies (Lifecycle Mgmt) | Marketed |
| Xywav/Xyrem | Narcolepsy / Idiopathic Hypersomnia | Marketed |
| Vyxeos | Acute Myeloid Leukemia (AML) | Marketed |
| Zepzelca | Relapsed Small Cell Lung Cancer (SCLC) | Marketed |
| Defitelio | Hepatic Veno-Occlusive Disease (VOD) | Marketed |
| Rylaze | Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma | Marketed |
| Sunosi | Excessive Daytime Sleepiness (Narcolepsy/OSA) | Marketed |
Leadership Team at Jazz Pharmaceuticals
RG
Renee Gala
President and Chief Executive Officer
LH
Liz Henderson
Senior Vice President, Technical Operations
RI
Robert Iannone, M.D., M.S.C.E.
Executive Vice President, Global Head of Research and Development, Chief Medical Officer
PL
Philip L. Johnson
Executive Vice President and Chief Financial Officer
RM
Robert Mackey
Senior Vice President, Global Product Commercialization
HM
Heidi Manna
Executive Vice President and Chief People Officer
JM
John Miller
Senior Vice President, Corporate Strategy
NM
Neena M. Patil
Executive Vice President and Chief Legal Officer
SP
Samantha Pearce
Executive Vice President, Chief Commercial Officer
TR
Thomas Riga
Senior Vice President, Chief Business Officer